Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Moehler

Showing results (151-160 of 218) with videos related to

Pageof 22
Sort By:
Nature Communications|September 4, 2023
The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancerAlexander J Ohnmacht, Arndt Stahler, Sebastian Stintzing, et al.
Oncotarget|December 30, 2017
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Oncology Research and Treatment|June 1, 2025
Guidelines of Onkopedia: What Is New?Magdalena K Scheck, Salah-Eddin Al-Batran, Markus Borner, et al.
JMIR Research Protocols|April 21, 2023
Digital Guardian Angel Supported by an Artificial Intelligence System to Improve Quality of Life, Well-being, and Health Outcomes of Patients With Cancer (ONCORELIEF): Protocol for a Single Arm Prospective Multicenter Pilot StudyJoaquim Reis, Luzia Travado, Alexander Scherrer, et al.
British Journal of Cancer|November 6, 2020
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trialVolker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
Oncoimmunology|September 14, 2020
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)Carl Christoph Schimanski, Stefan Kasper, Susanna Hegewisch-Becker, et al.
Human Gene Therapy|September 6, 2017
Virotherapy Research in Germany: From Engineering to TranslationGuy Ungerechts, Christine E Engeland, Christian J Buchholz, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 7, 2014
International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagusMarkus Moehler, Christoph T H Baltin, Matthias Ebert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
Amphiregulin Expression Is a Predictive Biomarker for <i>EGFR</i> Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized TrialsArndt Stahler, Sebastian Stintzing, Dominik P Modest, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2025
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trialKathrin Heinrich, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Pageof 22

Showing results (151-160 of 218) with videos related to

Sort By:
Pageof 22
Nature Communications|September 4, 2023
The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancerAlexander J Ohnmacht, Arndt Stahler, Sebastian Stintzing, et al.
Oncotarget|December 30, 2017
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Oncology Research and Treatment|June 1, 2025
Guidelines of Onkopedia: What Is New?Magdalena K Scheck, Salah-Eddin Al-Batran, Markus Borner, et al.
JMIR Research Protocols|April 21, 2023
Digital Guardian Angel Supported by an Artificial Intelligence System to Improve Quality of Life, Well-being, and Health Outcomes of Patients With Cancer (ONCORELIEF): Protocol for a Single Arm Prospective Multicenter Pilot StudyJoaquim Reis, Luzia Travado, Alexander Scherrer, et al.
British Journal of Cancer|November 6, 2020
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trialVolker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
Oncoimmunology|September 14, 2020
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)Carl Christoph Schimanski, Stefan Kasper, Susanna Hegewisch-Becker, et al.
Human Gene Therapy|September 6, 2017
Virotherapy Research in Germany: From Engineering to TranslationGuy Ungerechts, Christine E Engeland, Christian J Buchholz, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 7, 2014
International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagusMarkus Moehler, Christoph T H Baltin, Matthias Ebert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
Amphiregulin Expression Is a Predictive Biomarker for <i>EGFR</i> Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized TrialsArndt Stahler, Sebastian Stintzing, Dominik P Modest, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2025
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trialKathrin Heinrich, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Pageof 22